| Literature DB >> 35530690 |
Yun-Ming Qiao1, Rui-Lin Yu1, Ping Zhu1.
Abstract
The revolutionary discovery of penicillin only marks the start of our exploration for valuable fungal natural products. Advanced genome sequencing technologies have translated the fungal genome into a huge reservoir of "recipes" - biosynthetic gene clusters (BGCs) - for biosynthesis. Studying complex fungal genetics demands specific gene manipulation strategies. This review summarizes the current progress in efficient gene targeting in fungal cells and heterologous expression systems for expressing fungal BGCs of fungal secondary metabolites. This journal is © The Royal Society of Chemistry.Entities:
Year: 2019 PMID: 35530690 PMCID: PMC9074735 DOI: 10.1039/c9ra06908a
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Examples of gene targeting outcomesa
| Method | Host fungi | Target locus | Before | After | Notes | |
|---|---|---|---|---|---|---|
| NHEJ impair – Ku disruption |
|
| 1% | 64% | Increased sensitivity to certain antibiotics |
|
|
|
| 1% | 47% | Ku mutant showed reduced fitness when co-cultivated with the wild-type |
| |
|
| 56% | |||||
|
|
| 33% | 100% |
| ||
|
| 91% | 100% | ||||
|
|
| 0.42% | 70% | Genome instability at |
| |
|
|
| 15% | 88% |
| ||
| NHEJ impair – ligD disruption |
|
| 0% | 6%, 65%, 90% | Homology arm size = 500, 1000, 1500 bp |
|
|
|
| 0% | 25% | Numbers are estimates from graph |
| |
|
| 5% | 70% | ||||
|
| 5% | 40% | ||||
|
|
| 19% | 97% | Homology arm size = 500 bp |
| |
|
| 73% | 90% | ||||
|
| 0% | 27% | ||||
| ATMT |
|
| — | 0.001–0.01% |
| |
|
|
| 0% | 25.00% |
| ||
|
|
| 0% | 0.16% |
| ||
|
|
| 3% | 18.00%* | *: Best result obtained using |
| |
| CRISPR-Cas9 |
|
| 3% | 1% |
| |
|
|
| — | 21.43% |
| ||
|
|
| — | 60.00% | Homology arm size = 1000 bp |
| |
|
|
| 0% | *9.8–80.5% | *Depending on targeting sites and choice of promoter |
| |
|
|
| — | 93% | Homology arm size = 200 bp |
| |
|
|
| 0% | 30–100% |
| ||
|
| 0% | 8–100% | ||||
| NHEJ impair + ATMT |
|
| 6.5% | 93.4% |
| |
|
|
| 0.60% | 11.40% | Reduced growth at >28 °C; reduced conidia production at >26 °C |
| |
|
| 0% | 6.60% | ||||
| NHEJ impair + CRISPR-Cas9 |
|
| 0% | * | *: “most of the transformants” |
|
|
|
| 0% | 90% | |||
| ATMT + CRISPR-Cas9 |
|
| — | 67–100% |
| |
|
| — | 88.89% | ||||
|
|
| — | 27.1–39.1% | Cas9 and targeting cassette introduced at the same time |
| |
| Mfa2 (knock-in) | — | 74.50% | Cas9 present before introduction of targeting cassette |
“—” indicates data omitted in the paper. “Before”: frequency of precise gene targeting in wild-type (NHEJ impair) or protoplast-mediated transformation (ATMT). “After”: frequency of precise gene targeting after NHEJ impair, ATMT, or CRISPR-Cas technology.
Fig. 1Procedure of ATMT. (a) The T-DNA plasmid can be produced by recombinant E. coli. The plasmid is then transformed into Agrobacterium cells. Yellow: T-DNA borders. Red: gene of interest. (b) Acetosyringone induces expression of the vir genes which are located in the bacterial chromosome and in the helper plasmid. Pink: vir genes. (c) The vir genes direct the copy, gene transfer and incorporation of the T-DNA into the target cell.[28]
Heterologous expression outcomesa
| Host organism | Gene source | Gene name | Protein | Biosynthesis product | |
|---|---|---|---|---|---|
|
|
|
| Type I Baeyer–Villiger monooxygenase | Lactones |
|
|
|
| Chanoclavine-I aldehyde reductase | Festuclavine (EAS pathway) |
| |
|
|
| Festuclavine dehydrogenase | |||
|
|
| ||||
|
|
|
| α-Keto acids |
| |
|
|
| α-1,6-Glucosidase (isomaltase) | Glucose |
| |
|
|
| ||||
|
|
| ||||
|
|
| Non-ribosomal peptide synthetase | Pyrazine |
| |
|
|
|
| Catalase | Chanoclavine-I (EAS pathway) |
|
|
| FAD-dependent oxidoreductase | ||||
|
|
| Oxidase | Cycloclavine (EAS pathway) |
| |
|
| Reductase | ||||
|
| Dioxygenase | ||||
| Diverse ascomycete and basidiomycete fungal species | — | 22 BGCs with polyketide synthase or UbiA-type cyclase at its core | — |
| |
|
|
| P450 monooxygenase | Statin |
| |
|
| Polyketide synthase | ||||
|
| Enoyl reductase | ||||
|
| Transesterase | ||||
|
| Thioesterase | ||||
|
| HMG-CoA reductase | ||||
|
|
| Phosphopanetheinyltransferase | |||
|
|
|
| Dimethylallyltryptophan synthase | Chanoclavine-I (EAS pathway) |
|
|
| Methyltransferase | ||||
|
| Oxidoreductase | ||||
|
| Catalase | ||||
|
| — | 9 nonreducing polyketide synthases | — |
| |
|
| Regulator | Asperfuranone | |||
|
| Efflux pump | ||||
|
| Esterase/lipase | ||||
|
| Salicylate monooxygenase | ||||
|
| Nonreducing polyketide synthase | ||||
|
| FAD-dependent oxidase | ||||
|
| Highly reducing polyketide synthase | ||||
|
|
|
| Non-ribosomal peptide synthetase | Enniatin |
|
|
|
|
| Isomerase | Agroclavine (EAS pathway) |
|
|
| Dioxygenase | Lysergic acid (EAS pathway) | |||
|
| Clavine oxidase (P450 monooxygenase) | ||||
|
|
|
| Polyketide synthase | Monacolin K |
|
|
| P450 monooxygenase | ||||
|
| Oxidoreductase | ||||
|
| Dehydrogenase | ||||
|
| Transesterase | ||||
|
| HMG-CoA reductase | ||||
|
| Probable transcription factor | ||||
|
| Efflux pump | ||||
|
|
| Non-ribosomal peptide synthase | Terrequinone Q | ||
|
| Indoleprenyltransferase | ||||
|
| Oxidoreductase | ||||
|
| PLP-dependent transaminase | ||||
|
| Unknown protein | ||||
|
|
|
| Cellobiohydrolase | Cellobiose |
|
|
|
| Non-reducing peptide synthase | Orsellinic acid, 6,7-dihydroxymellein and 4-hydroxy-6-methylpyrone (terrein pathway) |
| |
|
| Transcriptional regulator | ||||
|
|
|
|
| Itaconic acid |
|
|
|
|
| Non-ribosomal peptide synthetase | Gramicidin S |
|
“—” indicates too much text to fit in the table.
Fig. 2The recombinant biosynthetic pathway of festuclavine, agroclavine, and cycloclavine from l-tryptophan and DMAPP in Saccharomyces cerevisiae.[78]